REYON Pharmaceutical Co., Ltd. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023
August 14, 2023 at 10:26 am
Share
REYON Pharmaceutical Co., Ltd. reported earnings results for the second quarter and six months ended June 30, 2023. For the second quarter, the company reported negative sales was KRW 0.00038 million compared to sales of KRW 0.00041 million a year ago. Net income was KRW 2,666.24 million compared to net loss of KRW 413.34 million a year ago. Basic earnings per share from continuing operations was KRW 149 compared to basic loss per share from continuing operations of KRW 25 a year ago. Diluted earnings per share from continuing operations was KRW 141 compared to diluted loss per share from continuing operations of KRW 25 a year ago. Basic earnings per share was KRW 149 compared to basic loss per share of KRW 25 a year ago. Diluted earnings per share was KRW 141.
For the six months, negative sales was KRW 0.00032 million compared to KRW 0.00032 million a year ago. Net income was KRW 4,673.65 million compared to KRW 1,481.11 million a year ago. Basic earnings per share from continuing operations was KRW 261 compared to KRW 80 a year ago. Diluted earnings per share from continuing operations was KRW 250 compared to KRW 80 a year ago. Basic earnings per share was KRW 261 compared to KRW 80 a year ago. Diluted earnings per share was KRW 250.
REYON PHARMACEUTICAL Co. Ltd. is a Korea-based company engaged in the provision of pharmaceutical products. The Companyâs products consist of remedies for circulatory systems, endocrine systems, digestive systems, respiratory systems, urinary systems and nervous systems, as well as eye drops, antibiotics, fever reducers, painkillers, anti-inflammatory drugs, antihistaminic agents, enzyme preparations, arthritis remedies, antitumor drugs and topical anesthetics, among others. It also produces pharmaceutical raw materials, such as arbekacin sulfate, alibendol, carvedilol, enocitabine, gemcitabine, glimepiride, lamotrigine, meloxicam, oxaliplatin, pioglitazone hydrochloride, ramipril, streptokinase, tacrolimus, thioctic acid, teicoplanin, voglibose and others.